Consolidated Financial Results (Tanshin)for the Fiscal Year Ended March 31, 2024 (Based on IFRS)

May 15, 2024
Name of listed company: CYBERDYNE Inc.

Stock exchange listing: Growth Section of TSE

Stock code
Representative (title): 7779: President and CEO

URL
Name

: https://www.cyberdyne.jp/english: Yoshiyuki SankaiContact (title): Director and COO

Name: Shinji Honda
Tel. +81-29-869-9981

Scheduled date ofOrdinary General Meeting of Shareholders
Scheduled date for submission of the Securities Report
Additional materials for the financial results
Information meeting for the financial results

Scheduled start of dividend payment : —: June 21, 2024
: June 24, 2024
: yes
: yes (for institutional investors)(Millions of yen: Rounded to less than one million yen)

Ⅰ. Consolidated financial results for the fiscal year ended March 31, 2024 (April 1, 2023 –March 31, 2024)

1. Consolidated result of operations(percentages denote year-on-year change)
Operating profit(loss)

Revenue％
Fiscal year ended
March 31, 2024
Fiscal year ended
March 31, 2023

Profit (loss) attributable toowners of parent％％

Profit (loss) before tax
％

4,354

32.4

(2,018)－(1,141)－(1,476)

－

3,289

52.9

(1,145)

－

53

－

(298)

－

Basic earnings (loss) Diluted earnings (loss)
per shareper share
Yen
Yen
Fiscal year ended
March 31, 2024
Fiscal year ended
March 31, 2023

(6.99)(6.99)(1.39)(1.39)

2. Consolidated financial position
Ratio of equity
Total equity
attributable to owners
Total equity
attributable to owners
Net assets per shareof the parent to totalof the parent
assetsMillions of yen
Millions of yen
Yen％

Total assets
Millions of yen
As of March 31, 2024

49,99940,47740,752

81.5

192.93As of March 31, 2023

50,187

41,983

42,101

83.9

199.32

3. Consolidated cash flows
Cash flows fromoperating activities
Millions of yen

Cash flows frominvesting activities
Millions of yen

Cash flows from
Cash and cash equivalents
financing activities
at end of year
Millions of yen
Millions of yen

As of March 31, 2024(850)

(2,075)

160

5,155

As of March 31, 2023

(143)

2,173

14

7,801

Ⅱ. Dividends

Dividends per share
End of
1st quarter(Jun.30, 2023)

End of
2nd quarter(Sep.30, 2023)

End of
3rd quarter(Dec.31, 2023)

Fiscal year end(Mar.31, 2024)

Yen

Yen

Yen

Yen

Yen

Fiscal year ended March 31, 2023

－

0.00

－

0.00

0.00

Fiscal year ended March 31, 2024

－

0.00

－

0.00

0.00

Total

Note: The table of “Dividends” indicates dividend payments on Common Shares. Dividend payments on Class Shares (non-listed) for
which the number of share units differs from Common Shares are shown below as “Dividends on Class Shares”.
Ⅲ. Forecast of consolidated financial results for the year ended March 31, 2024 (April 1, 2023 – March 31, 2024)
The business of CYBERDYNE, INC. (the "Company") and its group companies (with the Company, collectively referred to as“the Group”) are based on a new market with innovative technologies. Many uncertain factors could impact its performance andmake it difficult for the Company to forecast accurate figures. As such the Company will not announce the forecast of consolidated
financial results.

Notes:
1. Changes in key subsidiaries during the fiscal year under review (changes in specific subsidiaries resulting in changes of
consolidation scope): none
new: － (company name: － ) ,excluded: － (company name: － )2. Changes in accounting policies, accounting estimates and restatement of error corrections(i) Changes in accounting policies required by IFRSs: yes(ii) Changes in accounting policies other than those in (i): none(iii) Changes in accounting estimates: none
3. Total number of issued shares (Common Shares)(i) Total number of issued shares at the end of the period (including treasury shares)
As of March 31, 2024
215,145,809 shares As of March 31, 2023
(ii)

215,145,809 shares

Total number of treasury shares at the end of the period

As of March 31, 2024

4,014,574 shares

As of March 31, 2023

4,011,673 shares(iii) Average number of shares during the period
Apr.1-March 31, 2024
211,131,236 shares

Apr.1-March 31, 2023

214,706,740 shares

Note: Class B Shares are ranked the same as Common Shares and paid the same amount as Common Shares concerning
dividends of surplus and distribution of residual assets. Therefore, the total number of issued shares in each period andthe average number of shares during each period include Class B Shares as Common Shares.
*This Consolidated Financial Results (Tanshin) is outside the scope of audit procedures by certified public accountants or audit firms.

(Reference) Dividends on Class Shares
Details of dividends on the Company’s Class Shares which differ in shareholder's rights from its Common Shares are statedbelow.
Dividends per share
End of
1st quarter(Jun.30, 2023)

End of
2nd quarter(Sep.30, 2023)

End of
3rd quarter(Dec.31, 2023)

Fiscal year end(Mar.31, 2024)

Total

Yen

Yen

Yen

Yen

Yen

Fiscal year ended March 31, 2023

－

0.00

－

0.00

0.00

Fiscal year ended March 31, 2024

－

0.00

－

0.00

0.00

Note:
The company issued Class B Shares that have the same rights as Common Shares concerning dividends of surplus and distribution ofresidual property. However, the Class B Share has different share units from Common Shares.

○Contents of the Attached Material
1. Qualitative information regarding settlement of accounts for the fiscal year ended March 31, 2024・・・・・・・・・・・・・・(1) Explanation of operating results・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・

22(2) Explanation of financial position・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・(3) Status of cash flow・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・(4) Explanation related to the forecast of consolidated financial results and other forward-looking statements・・

55
5

2. Accounting standards・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・
3. Consolidated Financial Statements and Notes to consolidated financial statements・・・・・・・・・・・・・・・・・・・・・・・・・・・(1) Consolidated statement of financial position・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・

677(2) Consolidated statement of profit or loss and consolidated statement of comprehensive income・・・・・・・・・・・・

9

Consolidated statement of profit or loss・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・

9

Consolidated statement of comprehensive income・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・

10(3) Consolidated statement of changes in equity・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・(4) Consolidated statement of cash flows・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・(5) Notes to consolidated financial statements・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・(Notes on premise of going concern) ・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・

11
13
14
14

(Segment information) ・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・

14(Revenue) ・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・

15(Earnings per share) ・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・

16

- 1 -

1. Qualitative information regarding settlement of accounts for the fiscal year ended March 31, 2024
(1) Explanation of operating results
All forward-looking statements included in this explanation were determined reasonable by CYBERDYNE Inc. (the“Company”) and its group companies (collectively referred to as the “Group”) based on currently available information for the
consolidated March 31, 2024, and certain assumptions made by the Group.
To solve various issues facing society, the Group will make full use of “Cybernics” (a new field that integrates and combines
human, robot, AI, and information systems) and handle HCPS (Human-Cyber-Physical Space) in a unified manner.
Furthermore, through Cybernics, the Group promotes the realization of “Techno Peer Support” and future development by
creating the “Cybernics Industry,” a new industry that will follow the robotics and IT industries.
The Group defines “Techno Peer Support Society” as a safe and secure society where people and technology coexist,
cooperate and mutually support each other to enhance the independence and freedom of people of all generations and solve
various problems in their lives both mentally and physically. To realize Techno Peer Support Society and Cybernics Industry,
the Group is developing various Cybernics Technologies that improve, regenerate, expand, and support the wearer’s physicalfunctions.
Status of business operation<<Business operation around the medical application>>
The Group continues its efforts to disseminate Cybernics Treatment, a treatment program using Medical HAL systems thataims to induce improvement and regeneration of the functions of the brain, nerves, and muscles into a global standard oftreatment.
(Japan)The Group continues its efforts to disseminate Cybernics Treatment, a treatment program using Medical HAL. Postmarketing surveillance on the Medical HAL Lower Limb Type Double-leg Model suggested a high efficacy and safety
towards progressive neuromuscular diseases, for which no effective treatment methods are available in the medical world yet.
Based on the extremely high efficacy and safety results obtained in post-market surveillance, Medical HAL Lower Limb Typewas given increased points in the 2022 revision of medical treatment fees as “a remarkable functional improvement effectunprecedented in patients with progressive neuromuscular diseases for which no other effective treatment methods have been
established, including already approved drugs” (excerpt from the medical technology evaluation proposal by the JapaneseSociety for Neurological Therapeutics).
Regarding spinal cord-related diseases, the Japanese Minister of Health, Labor, and Welfare approved additional indicationsof HTLV-1-associated myelopathy (HAM) and hereditary spastic paraplegia for HAL on October 2022. Regarding traumatic
spinal cord injuries, the Company is consulting with the regulators on the necessary steps to obtain medical device approvals.
Regarding stroke, the Company discussed the result of the investigator-initiated clinical trial using the Medical HAL Lower
Limb Type single-leg model (HIT2016 trial). Considering the practice conditions surrounding acute stroke treatment andrecovery rehabilitation, the Company is preparing additional studies (clinical trials) while consulting with the regulator.
In addition, the University of Tsukuba Hospital started clinical trials to investigate the effect of HAL on improving thephysical functions of children affected by cerebral palsy in January 2022. The clinical trial is currently in progress. The
Company has also developed a small Medical HAL Lower Limb Type model equivalent to the device used in the clinical trial
for cerebral palsy. The Company submitted paperwork to obtain approvals from the PMDA (Pharmaceuticals and Medical
Devices Agency) in June 2023 for the same group of patients as the larger size of Medical HAL Lower Limb Type.
(USA)
As a medical service platform for individual users, RISE Healthcare Group (RHG), the Company’s subsidiary, is gradually
expanding the number of facilities, mainly in the Southern part of California. Four RHG facilities currently offer fee-based
service using HAL, and the number of treatment sessions is increasing steadily.
The Company also obtained marketing clearance for a smaller Medical HAL Lower Limb Type model and additional
indication of cerebral palsy (above 12 years old) from the U.S. FDA. With the approval of the smaller model as a medical
device, patients between 100 cm and 150 cm in height can now be treated with Medical HAL. In addition, the company also
received approval to expand the indications for the treatment of HTLV-1-related myelopathy (HAM) and hereditary spastic
paraplegia which were already approved in Japan.

- 2 -Based on the accumulated experience of Cybernics Treatment in the U.S., the approval of a smaller model of Medical HAL,
and the expansion of approved diseases, the Company will continue to expand the business in this region.
(EMEA: Mainly Europe and the Middle East)
The Group continues to promote Cybernics Treatment in the region. For example, following large-scale installation of HAL in
Türkiye, 25 units of HAL was shipped out to an Italian Social Company, Coopselios, in May 2023. The Company is planningto ship out additional units.
In Germany, the G-BA (German Federal Joint Committee), the public health insurance authority, has announced that it willconduct a clinical trial for spinal cord injury based on public health insurance coverage. Related parties are preparing for thetrial.
(APAC: Asia Pacific)
CYBERDYNE MALAYSIA Sdn. Bhd. is working to disseminate Cybernics Treatment in a wide area of South East Asia,
India, Australia, and Taiwan.
The Group continues to strengthen its partnership with Malaysia’s government-affiliated Social Security Organization(SOCSO). The collaboration resulted in increased access for Malaysian patients under the SOCSO coverage, and the treatment
is currently offered in twelve facilities through 112 income-generating rental units as of the end of March 2024. Constructionof the National Center for Neuro-Robotics and Cybernics, the largest medical complex in Southeast Asia, is scheduled forcompletion by the end of 2024. The Group expects to install significant numbers of HAL in this center.
<<Business operation around applications to support caregivers and care receivers>>
The Group has developed various types of HAL for seniors to improve their physical function, prevent illness and frailty, andreduce the requirement for care. These include the HAL Lower Limb Type for enhancing the ability to walk, the HAL Single
Joint Type to train elbow, knee, and ankle movements, and the HAL Lumbar Type to train the trunk and lower limb function.
(Service at facilities for individuals)
The Group continues to offer Neuro HALFIT, a program that induces improvement of the brain-nerve and musculoskeletal
system through utilizing HAL. The program is currently available at 18 Robocare Centers operated by business partners. The
Group plans to open additional Robocare Centers.
(Neuro HALFIT at Home as a service towards individuals)
Neuro HALFIT at Home is a home-based program in which individuals rent HAL and engage in HAL-assisted workouts at
Home. The HAL Monitor, which is linked to Cyberdyne's cloud and visualizes bio-electricla signals that command body
movements and posture information, enables the wearer to obtain visual feedback as well. The HAL Monitor, which is linked
to Cyberdyne's cloud and visualizes bioelectrical signals that command body movements and posture information, enables thewearer to obtain visual feedback as well. In addition to providing online support by therapists, trainers, and other professional
staff, the Company also work with home-based service providers to promote in-person support, from setting up equipment athome to implementing programs.
<<Prevention/early detection>>
The Group is preparing for the commercialization of the Cyvis series, an ultra-small size vital sensor designed to manage therisk of arrhythmia and atrial fibrillation and prevent myocardial infarction, and stroke by accumulating, analyzing, andprocessing various healthcare data such as cardiac activity, brain activity, body temperature, SpO2, and daily activities using
its AI system. Cyvis also has an optional feature to measure breathing conditions while sleeping, enabling easy yet highly
accurate screening of risks of sleep apnea syndrome. In addition, together with “JUKUSUI Alarm,” a healthcare applicationthat visualizes sleep, developed and operated by group company C2, the Group is strengthening its healthcare business as awhole. The Company submitted a medical device approval application for its next-generation model, Cyvis 2, on April 2023.
<<Business operation around applications for the workplace and daily life>>(Well-being)
From 2021, the Company have used the operation of the HAL Lumbar Type f in nursing care facilities in Hampshire, U.K., asa model case. The Company will continue to work with Hampshire County to expand the system to other areas in the U.K. andto other European countries.

- 3 -(Labor Support, Disinfection, and Cleaning)
Regarding the next-generation Cleaning Robot CL02, which uses cutting-edge SLAM technology to achieve high-speed
autonomous driving, the Group works with major construction companies with its ability to ride on elevators automaticallyand connect with cloud systems; the companies are developing this technology as a solution to make building management
smarter and reduce management costs. Furthermore, the company is expanding its mobility part as a transportation robot
inside the factory.
Status of Research and Development
The Group develops “Acoustic X,” a patented photoacoustic imaging system based on the LED light source method thatrealizes real-time, high-resolution 3D imaging of blood vessels and blood in the peripheral organs without needing contrast
agents. The Group develops this technology as a next-generation medical image diagnosis device. In addition, research isunderway at prominent medical institutions and research facilities around the globe to create various applications for thistechnology.
Furthermore, the proposal of the Group was selected for the next Cross-ministerial Strategic Innovation Promotion Program(SIP) Third Phase: Development of Fundamental Technologies, the Establishment of Common Systems, Rules, andRegulation for the Expansion of Human Collaborative Robotics, Theme 6: Development of Social Implementation
Technologies for HCPS* Integrated Human Collaborative Robotics to Solve Social Issues” that is led by the Council for
Science, Technology, and Innovation (the Cabinet Office of Japan). Under this program, the Group continues to (i) develop
an application for various living spaces such as residences, facilities, and workplaces, (ii) utilize HCPS-integrated Cybernics
master remote control technology that works together with human information (physiological, physical, behavioral, cognitive,
psychological, etc.), (iii) acquire and utilize human information obtained through non-invasive HCPS-integrated humancollaborative robotics, and (iv) Establish links with other related technologies of the R&D theme to improve the independence
and freedom of seniors and people with limited access to transportation.
At the Tonomachi International Strategic Zone (King Sky Front) in Kawasaki City, construction of the Cybernics Medical
Innovation Base Building A was completed to promote the systematization of Cybernics Treatment by combining HAL withregenerative medicine and drugs, and the development of technologies that integrate medical and bio-related technologies withAI, robotics and information systems. The Company will continue to coordinate with its C-Startup partners in the field of
regenerative medicine and drug creation.
Numbers of operating units
As of the end of March 2024, 474 Medical HAL Lower Limb Type units were operating worldwide, including those used forclinical research. ninety of those units were used in Japanese hospitals for treatment. In addition, there were 620 units of HAL
Single Joint Type, mainly from the increase of products for medical use. A total of 364 units of HAL for Well-being Lower
Limb Type and HAL for Living Support Lower Limb Type (older model) were in operation. Furthermore, 1,016 units of HAL
Lumbar Type for Well-being were in operation. In addition, there were 394 units of HAL Lumbar Type for Labor Support and
172 units of Cleaning Robots and Transportation Robots.
Due to the abovementioned situation, in the consolidated fiscal year that ended March 31, 2024, the increase of rental of
Medical HAL outside Japan and revenue through its services contributed to the revenue recorded at ¥4,354 million (32.4%
increase year on year). In addition, the Group recorded a gross profit of ¥2,393 million (33.6% increase year on year).
The Group recorded research and development expenses at ¥877 million (19.4% increase year on year), mainly due todeveloping new products at the Company's own cost and consigned research projects. In addition, the Group recorded otherselling, general, and administrative expenses at ¥3,251 million (35.2% increase year on year) due to M&A.
Other income was recorded at ¥424 million (100.0% increase year on year), mainly from consigned research project. Other
expenses were recorded at ¥707 million (¥8 million in the previous fiscal year), mainly due to the posting of impairment
losses on goodwill related to a domestic subsidiary, C2, Inc. As a result, the Group recorded an operating loss of ¥2,018
million (¥1,145 million in the previous fiscal year).
The Group recorded a finance income of ¥543 million, mainly due to gains from the valuation difference of investment
securities, gains related to CEJ Fund at ¥796 million and income tax expense at ¥507 million from deferred tax expenses,
resulting in the posting of loss attributable to owners of the parent at ¥1,476 million (¥298 million in the previous fiscal year).
The Company forms business and capital alliances with various startup companies that develop unique technologies. The
Company calculates the fair value of unlisted stocks of such companies using the IFRS 9 Financial Instruments. As a result,during the consolidated fiscal year ended March 31, 2024, The Group recorded ¥1,549 million in the gain on valuationdifference of investments securities as finance income and gains related to CEJ Fund. Also, the Group recorded ¥393 million- 4 -in the loss on valuation difference of investment securities as financial expenses and losses related to CEJ Fund. Furthermore,
the Group recorded ¥531 million as deferred tax expense associated with this valuation as an income tax expense andreclassified ¥587 million to third-party interest in CEJ Fund. As a result, the impact of calculating the fair value towards the
profit (loss) attributable to owners of a parent in the consolidated fiscal year was ¥38 million.
(2) Explanation of financial position① Assets:
For the consolidated fiscal year ended March 31, 2024, assets decreased ¥188 million to ¥49,999 million compared to theend of the previous fiscal year. Changes were mainly due to an increase of ¥1,997 million in other financial assets(current), ¥1,173 million in other financial assets (non-current) and ¥134 million in trade and other receivables, partially
offset by a decrease of ¥2,646 million in cash and cash equivalent, ¥396 million in goodwill, and ¥170 million inproperty, plant and equipment.
② Liabilities:
For the consolidated fiscal year ended March 31, 2024, liabilities increased ¥1,319 million to ¥9,523 million compared tothe end of the previous fiscal year. The changes were mainly due to an increase of ¥941 million in contributions to CEJ
Fund from third-party investors and ¥463 million in deferred tax liabilities.
③ Equity:
For the consolidated fiscal year ended March 31, 2024, equity decreased ¥1,506 million to ¥40,477 million compared to theend of the previous fiscal year. Changes were mainly due to a decrease of ¥1,476 million in retained earnings.
(3) Status of cash flow
For the consolidated fiscal year ended March 31, 2024, cash and cash equivalents increased ¥2,646 million to ¥5,155 million
compared to the end of the previous fiscal year. The main influence factors for the cash flow status within the consolidated
fiscal year ended March 31, 2024, are stated below.
(Cash flows from operating activities)
For the consolidated fiscal year ended March 31, 2024, net cash provided by operating activities recorded an outflow of 850
million (outflow of ¥143 million in the previous consolidated fiscal year). Changes were mainly due to depreciation andamortization posted at ¥677 million, and impairment loss posted at ¥660 million partially offset by a gain related to CEJ Fundrecorded at ¥796 million, finance income recorded at ¥543 million, and outflow of ¥134 million due to increase of trade andother receivables.
(Cash flows from investment activities)
For the consolidated fiscal year ended March 31, 2024, net cash provided by investing activities recorded an outflow of 2,075
million (an inflow of ¥2,173 million in the previous consolidated fiscal year). The changes were mainly due to the proceeds ofredemption of investments posted at ¥18,000 million, proceeds from the sale of investment securities posted at ¥572 million,
partially offset by the acquisition of investments posted at ¥20,000 million, and purchase of investment securities posted at¥455 million.
(Cash flows from financing activities)
For the consolidated fiscal year ended March 31, 2024, net cash used in financing activities recorded an inflow of ¥160 million(an inflow of ¥14 million in the previous consolidated fiscal year). The changes were mainly due to distribution and redemption
from CEJ Fund into third-party investors posted at ¥320 million and repayment of lease liabilities posted at ¥174 million,
partially offset by the inflow of ¥680 million from contributions to CEJ Fund from third-party investors.
(4) Explanation related to the forecast of consolidated financial results and other forward-looking statements
As the business of the Company and the Group is based on a new market with innovative technologies, there are many
uncertain factors that could have an impact on its performance and make it difficult for the Company to provide a forecast withaccurate figures. As such the Company will not announce the forecast of consolidated financial results.

- 5 -2. Accounting standards
The Group adopts International Financial Reporting Standard (IFRS) from the consolidated financial statements and the Annual
Securities Report for the fiscal year ended March 31, 2018, with the aim of improving the international comparability of theGroups' financial information in the capital markets and strengthening the Groups' business foundations by unifying accounting
standards throughout the Group.

- 6 -3. Consolidated financial statements and Notes to consolidated financial statements(1) Consolidated statement of financial position

As of March 31, 2023

As of March 31, 2024

Millions of yen

Millions of yen

AssetsCurrent assets
Cash and cash equivalents

7,801

5,155

Trade and other receivables
Other financial assets

540
9,507

674
11,504Inventories

991

997

Other current assets

308

139

Total current assets

19,147

18,469430
13,406359
13,237

546

482

2,531

2,134

80
240

48
261

Other financial assets

13,641

14,814

Other non-current assets

166

196

Total non-current assets

31,04031,53050,18749,999Non-current assets
Operating lease assets
Property, plant and equipment
Right of use assets
Goodwill
Intangible assets
Investments accounted for using equity method

Total assets- 7 -As of March 31, 2023

As of March 31, 2024

Millions of yen

Millions of yen

Liabilities and equity
Liabilities
Current liabilities
Trade and other payables
Bonds and borrowings

690
89

606
84

Lease liabilities

147

160

Other current liabilities
Total current liabilities

365

386

1,291

1,236

Non-current liabilities
Bonds and borrowings

21

22

Third-party interests in CEJ Fund
Lease liabilities

4,792
412

5,733
366

Provisions
Deferred tax liabilities

96
1,577

96
2,040

Other non-current liabilities

14

30

Total non-current liabilities

6,913

8,286

8,204

9,523

10

10

Capital surplus
Treasury shares
Other components of equity
Retained earnings

42,877(1,188)
(979)
1,381

42,811(1,188)(787)(95)

Total equity attributable to owners of the parent

42,10140,752

Non-controlling interests
Total equity

(118)

(275)

41,98340,477

Total liabilities and equity

50,18749,999Total liabilities
EquityShare capital- 8 -(2) Consolidated statement of profit or loss and consolidated statement of comprehensive income(Consolidated statement of profit or loss)
Fiscal year ended
March 31, 2023

Fiscal year ended
March 31, 2024

Millions of yen
3,289

Millions of yen
4,354

Cost of sales(1,498)(1,961)Gross profit

1,791

2,393

Revenue

Selling, general and administrative expenses
Research and development expenses

(735)

(877)

Other selling, general and administrative expenses(2,406)(3,251)

Total selling, general and administrative expenses
Other income(3,140)212(4,129)424

Other expenses

(8)

(707)

(1,145)
1,312
(193)

(2,018)543(482)

Gains related to CEJ Fund

274

796

Share of profit (loss) of investments accounted for using equity
method(195)

21

Profit (loss) before tax

53(1,141)

Income tax expense

(446)

(507)

Profit (loss)(393)(1,648)

Profit (loss) attributable to
Owners of parent
Non-controlling interests

(298)
(95)

(1,476)
(172)

(393)

(1,648)

Basic earnings (loss) per share (yen)(1.39)(6.99)

Diluted earnings (loss) per share (yen)(1.39)(6.99)

Operating profit (loss)
Finance income
Finance costs

Profit (loss)
Earnings (loss) per share- 9 -(Consolidated statement of comprehensive income)Fiscal year ended
March 31, 2023

Fiscal year ended
March 31, 2024

Millions of yen(393)

Millions of yen(1,648)Financial assets measured at fair value through othercomprehensive income

36

(59)

Total of items that will not be reclassified to profit or loss

36

(59)

Exchange differences on translation of foreign operations

134

231

Total of items that may be reclassified to profit or loss

134

231

170

172

(223)

(1,477)

Owners of parent(131)(1,284)Non-controlling interests

(91)

(193)

Comprehensive income(223)(1,477)

Profit (loss)
Other comprehensive income
Items that will not be reclassified to profit or loss

Items that may be reclassified to profit or loss

Total other comprehensive income, net of tax
Comprehensive income
Comprehensive income attributable to- 10 -

(3) Consolidated statement of changes in equity
Fiscal year ended March 31, 2024
Equity attributable to owners of parent
Other components of equity

Share capital

Capital surplus

Treasury shares

Millions of yen

Millions of yen

Millions of yen

Financialassetsmeasured atfair value
through othercomprehensive
incomeMillions of yen

Millions of yen

Millions of yen

10

42,869(0)(1,306)

142

19

－
－

－
－

－
－

－
36

－
130

－
－

－
－

－
8

130

－

－

－
－

Acquisition of treasury shares

－

－

－
－
(1,188)36

Share-based payment transactions

－

－

－

－

－

－

－

－

－

－

－

－

－

－

－

－

－

－

－

－

－

－

8

(1,188)－－－March 31, 2023

10

42,877(1,188)(1,270)272

19Profit (loss)

－

－

－

－

－

－

－
251

－

Other comprehensive income

－
(59)

－

－
7

－

(59)

251

－

－

－
(0)

－
－

－
－

－
－

－

(73)

－

－

－

－

－
－

－
－

－
－

－
－

－
－

－
－

April 1, 2022
Profit (loss)
Other comprehensive income
Total comprehensive income

Equity transaction with non-controllinginterest
Increase (decrease) by business combination
Other
Total transactions with owners

Total comprehensive income
Share-based payment transactions
Acquisition of treasury shares
Equity transaction with non-controllinginterest
Increase (decrease) by business combination
Other
Total transactions with owners
March 31, 2024－－

Exchangedifferences ontranslation offoreign
operations

Share
acquisitionrights

－

－

(66)

(0)

－

－

－

10

42,811(1,188)(1,329)523

19- 11 -

Equity attributable to owners of parent
Other
components ofequityNon-controllinginterests

Total equity

Millions of yen
43,413

Millions of yen
38

Millions of yen
43,450

－

(298)
166

(95)
4

(393)
170
(223)

Retainedearnings

Total

Millions of yen(1,145)

Millions of yen
1,679

－
166

(298)

Total

April 1, 2022
Profit (loss)
Other comprehensive income
Total comprehensive income

166

(298)

(131)

(91)

Share-based payment transactions

－

－

8

－

8

Acquisition of treasury shares
Equity transaction with non-controlling－－(1,188)－(1,188)

－

－

－

9

9

－
－

－
－

－
－

(75)
2

(75)
2

interest
Increase (decrease) by business combination
Other
Total transactions with owners－－(1,180)(65)(1,244)

March 31, 2023

(979)

Profit (loss)

－
192

1,381
(1,476)

42,101(1,476)

(118)
(172)

41,983(1,648)Other comprehensive income

－

192

(21)

172

Total comprehensive income

192(1,476)(1,284)(193)(1,477)

Share-based payment transactions
Acquisition of treasury shares

－
－

－
－

7
(0)

－
－

7
(0)

－

－

(73)

31

(42)

－

－

－

－

－

－

－
5

－
5

Equity transaction with non-controllinginterest
Increase (decrease) by business combination
Other
Total transactions with owners
March 31, 2024

－

－

(66)

36

(30)

(787)

(95)

40,752(275)

40,477- 12 -

(4) Consolidated statement of cash flows

Cash flows from operating activities
Profit (loss) before tax
Depreciation and amortization
Impairment loss
Finance income
Finance costs
Gains related to CEJ FundFiscal year ended
March 31, 2023

Fiscal year ended
March 31, 2024

Millions of yen

Millions of yen
53(1,141)

627

677
660

－
(1,312)
193

(543)
482

(274)

(796)

Share of loss (profit) of investments accounted for using equity
methodDecrease (increase) in inventories
Decrease (increase) in trade and other receivables

195

(21)

98
(275)

(6)
(134)

Increase (decrease) in trade and other payables
Other

379
261

(85)
88

(55)

(819)

20
(0)

27
(0)

Income taxes refund
Payments for administrative expenses etc. related to CEJ Fund

－
2
(110)

－
(52)

Net cash provided by (used in) operating activities

(143)

(850)

SubtotalInterest and dividends received
Interest paid
Income tax paid

Cash flows from investing activities
Purchase of investments(7)(15,000)(20,000)

Proceeds of redemption of investments
Payments into time deposits
Proceeds from withdrawal of time deposits

18,000(2,000)4,500

18,000Purchase of property, plant and equipment

(451)

－
－
(216)

Purchase of intangible assets

(58)

(8)

(3,309)
556

(455)
572

(23)

－

(69)

(3)

13
14

5
29

2,173

(2,075)

(12)

(10)

Purchase of treasury shares
Lease liabilities paid

(1,188)
(153)

(0)
(174)

Contributions into CEJ Fund from third-party investors

1,380

680

Distributions and redemptions from CEJ Fund into third-party
investors

－

(320)

Other

(13)

(16)

Net cash provided by (used in) financing activities

14

160

80

120

Cash and cash equivalents at beginning of fiscal year

2,124
5,677

(2,646)
7,801

Cash and cash equivalents at end of year

7,801

5,155

Purchase of investment securities
Proceeds from sale of investment securities
Purchase of stock of subsidiaries with change of scope of
consolidation
Payments for loan receivables
Collection of loans receivable
Other
Net cash provided by (used in) investing activities
Cash flows from financing activities
Repayments of long-term borrowings

Effect of exchange rate changes on cash and cash equivalents
Net increase (decrease) in cash and cash equivalents- 13 -

(5) Notes to consolidated financial statements(Notes on premise of going concern)
There are no items to report.

(Changes in accounting policy)
Significant accounting policies applied to the condensed consolidated financial statements for the fiscal year ended March 31,
2024 are the same as those applied to the consolidated financial statements for the fiscal year ended March 31, 2023, with thefollowing exceptions.

IFRSs
IAS 12

Income Taxes

Nature of the new standards amendments
Revised clarification of deferred tax accounting for leases anddecommissioning obligations

The effect of applying these accounting standards on the Group’s condensed consolidated financial statements is not material.

(Segment information)
Segment information:
Fiscal year ended March 31, 2023 (from April 1, 2022 to March 31, 2023)
Since the company group had a single segment, segment information was omitted.
Fiscal year ended March 31, 2024 (from April 1, 2023 to March 31, 2024)
Since the company group had a single segment, segment information was omitted.

- 14 -

(Revenue)
Disaggregation of revenue
Details of disaggregation of revenue are set forth below.
Fiscal year ended
March 31, 2023

Fiscal year ended
March 31, 2024

Millions of yen

Millions of yen

Timing of revenue recognition
Service transferred over time

1,666

2,301

Asset transferred at a point of time
Service transferred at a point of time

202
1,421

273
1,779

3,289

4,354

Total

(Note) Since the Group operates under a single segment of business, segment information on revenue is omitted.
Service transferred over time
Service transferred over time includes rental income based on the individual rental contract and maintenance income
based on the maintenance contract in relation to finance lease income where the Group acts as a lessor of right-of-use
asset.
The Group recognizes rental income as income generated throughout the rental period after the customer acceptance ofthe relevant product, by either of the following method. Pay-per-use model based on times of product usage in therelevant month and base fee model based on fixed monthly price.
The Group recognizes maintenance income as performance obligation satisfied over time. The Company records thisrevenue during this contract period based on average amount during the period.
The Group recognizes usage fee revenue from the provision and operation of applications for smartphones as revenue
over time, as services are provided through the applications over a fixed period of time.
The Group recognizes sponsorship income by providing the right to indicate sponsorship through a title sponsorshipcontract over a fixed time.
Asset transferred at a point of time
Asset transferred at a point of time includes revenue from sales of commodities and products based on sales contract.
The Group mainly determines that performance obligation of sales of commodities as well as products are satisfied at
the point of customer acceptance the relevant product. The Group receives most of the payment within one month fromthe point of satisfying the performance obligation. With regards to transaction price, there is no significance in theamount of sales revenue that includes variable consideration. Furthermore, there are no significant financial components
in the amount of promised consideration.
Furthermore, if the Group acts as a lessor of right-of-use of its devices such as HAL, the Group classifies the relevant
lease as finance lease. Finance lease income is processed in the same way as cases where the Group acts as a lessor of
manufacturer or distributor of sales of goods. The Group determines that performance obligation is satisfied at the pointof customer acceptance and the revenue is recognized at a point of time.
Service transferred at a point of time
Service transferred at a point of time includes revenue from offering Cybernic Treatment and training service at Cybernic
Treatment Center and Robocare Centers to end-users (such as patients). In addition, the Company also includes revenue
received in return for providing outcomes of consigned research projects in this category.
The Group determines that the performance obligation of Cybernic Treatment and training services are satisfied at the
point of completion of such services. Furthermore, the Group determines that the performance obligation of providing
outcomes of consigned research projects is satisfied when the customer inspects and accepts the work.

- 15 -

(Earnings per share)
1. The basis for calculating basic earnings per share
Fiscal year ended
March 31, 2023
Loss attributable to owners of parent(298)(1,476)

－

－

(298)

(1,476)

214,706,740

211,131,236(1.39)(6.99)(Millions of yen)Amount not available for common shareholders and shareholders
equivalent to common shareholders(Millions of yen)
Loss used to calculate basic earnings per share(Millions of yen)
Average number of common shares and shares equivalent tocommon shares during the period (Shares)
Basic earnings (loss) per share (Yen)

Fiscal year ended
March 31, 2024

2. The basis for calculating diluted earnings per share
Fiscal year ended
March 31, 2023
Loss used to calculate basic earnings per share(Millions of yen)

(298)

(1,476)

－

－

(298)

(1,476)

214,706,740

211,131,236－－

214,706,740

211,131,236(1.39)(6.99)

Adjustments to loss (Millions of yen)
Loss used to calculate diluted earnings per share(Millions of yen)
Average number of common shares and shares equivalent tocommon shares during the period (Shares)
Adjustment *Note
Average number of diluted common shares and shares equivalent tocommon shares during the period (Shares)

Fiscal year ended
March 31, 2024

Diluted earnings (loss) per share (Yen)(Note) Summary of potential shares not included in the calculation of diluted earnings per share as it does not havedilutive effects
Fiscal year ended
Fiscal year ended
March 31, 2023
March 31, 2024
SharesShares2015 1st Series Stock Option of CYBERDYNE, INC.

(Common share)

7,800(Common share)

7,800

2016 1st Series Stock Option of CYBERDYNE, INC.

(Common share)

4,600(Common share)

4,600

2017 1st Series Stock Option of CYBERDYNE, INC.

(Common share)

10,500(Common share)

10,500- 16 -